Clinical Cancer Research · 2011 · 168 citations · 16 references
MedicineOncologyPharmacologyCancer PharmacologyOncology PharmacotherapySolid Tumor PharmacotherapyDose Adjustment In OncologyDose SchedulingPharmacodynamics Of Anticancer DrugsPharmacokinetics Of Anticancer DrugsToxicity ManagementAdverse Drug EventsDose-limiting Hematologic ToxicityDose-limiting Toxicity AssessmentPhase I Oncology TrialsPolo-like Kinase InhibitionPolo-like Kinase InhibitorsProtein Kinase InhibitorsTreatment Cycle Scheduling
PURPOSE: GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1). A phase I study of two schedules of intravenous GSK461364 was conducted. EXPERIMENTAL DESIGN: GSK461364 was administered in escalating doses to patients with solid malignancies by two schedules, either on days 1, 8, and 15 of 28-day cycles (schedule A) or on days 1, 2, 8, 9, 15, and 16 of 28-day cycles (schedule B). Assessments included pharmacokinetic and pharmacodynamic profiles, as well as marker expression studies in pretreatment tumor biopsies. RESULTS: Forty patients received GSK461364: 23 patients in schedule A and 17 in schedule B. Dose-limiting toxicities (DLT) in schedule A at 300 mg (2 of 7 patients) and 225 mg (1 of 8 patients) cohorts included grade 4 neutropenia and/or grade 3-4 thrombocytopenia. In schedule B, DLTs of grade 4 pulmonary emboli and grade 4 neutropenia occurred at 7 or more days at 100 mg dose level. Venous thrombotic emboli (VTE) and myelosuppression were the most common grade 3-4, drug-related events. Pharmacokinetic data indicated that AUC (area under the curve) and C(max) (maximum concentration) were proportional across doses, with a half-life of 9 to 13 hours. Pharmacodynamic studies in circulating tumor cells revealed an increase in phosphorylated histone H3 (pHH3) following drug administration. A best response of prolonged stable disease of more than 16 weeks occurred in 6 (15%) patients, including 4 esophageal cancer patients. Those with prolonged stable disease had greater expression of Ki-67, pHH3, and Plk1 in archived tumor biopsies. CONCLUSIONS: The final recommended phase II dose for GSK461364 was 225 mg administered intravenously in schedule A. Because of the high incidence (20%) of VTE, for further clinical evaluation, GSK461364 should involve coadministration of prophylactic anticoagulation.
16
Michael J. Hendzel, Wei Yi, Michael A. Mancini et al. · Chromosoma · 1997 · 1.9K citations
Incidence of Venous Thromboembolism in Patients Hospitalized with Cancer
Paul D. Stein, Afzal Beemath, Frederick A. Meyers et al. · The American Journal of Medicine · 2006 · 565 citations
Medicine, Hematology, Oncology +12